Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Colipral®, Placebo.
- Who it may be relevant to
- Registry conditions: Post-Colonoscopy Gastrointestinal Symptoms. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of the Effectiveness of Escherichia Coli 5C in the Management of Post-Colonoscopy Symptoms: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Overview
This prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of Escherichia coli 5C (Colipral®) in adult patients undergoing diagnostic colonoscopy. Participants will be randomized in a 1:1 ratio to receive either Colipral® or placebo for 14 days immediately after colonoscopy. The study aims to determine whether Colipral® reduces post-colonoscopy gastrointestinal symptoms compared with placebo, using validated symptom and stool assessment tools, patient-reported global improvement, and safety monitoring.
Detailed description
Patients undergoing diagnostic colonoscopy may experience gastrointestinal discomfort in the days following the procedure, which may be related to alterations in the intestinal microbiota induced by bowel preparation. This study is designed to evaluate whether supplementation with Escherichia coli 5C (Colipral®) can reduce post-colonoscopy gastrointestinal symptoms compared with placebo.
This is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Adult patients undergoing complete diagnostic colonoscopy will be screened according to predefined inclusion and exclusion criteria and enrolled after written informed consent. Participants will be randomly assigned in a 1:1 ratio to receive either Colipral® or placebo for 14 days immediately following colonoscopy. The study treatment will be administered as 2 capsules per day, with 1 capsule in the morning and 1 capsule in the evening after dinner.
Clinical assessments will be performed at baseline and at 48 hours, 7 days, and 14 days after colonoscopy. The primary efficacy endpoint is the between-group difference in change in Gastrointestinal Symptom Rating Scale (GSRS) total score from baseline to Day 7. Secondary efficacy assessments include GSRS score changes at additional time points, numerical rating scale (NRS) symptom scores, stool consistency, bowel movement frequency, patient global impression of change, use of rescue medication, treatment adherence, tolerability, and adverse events.
The study is designed to assess both the clinical efficacy and safety of Colipral® in the management of post-colonoscopy symptoms in adult patients.
Interventions
- Dietary supplement Colipral®
Dietary supplement containing Escherichia coli 5C (Colipral®) - Other Placebo
Matching placebo
Primary outcome measures
- Change in Gastrointestinal Symptom Rating Scale (GSRS) score [Time frame: Baseline to Day 7 after colonoscopy]
Secondary outcome measures (12)
- Change in Gastrointestinal Symptom Rating Scale (GSRS) total score at Day 14 [Time frame: Baseline to Day 14 after colonoscopy]
- Change in abdominal pain intensity score [Time frame: 48 hours, Day 7, and Day 14 after colonoscopy]
- Change in abdominal bloating intensity score [Time frame: 48 hours, Day 7, and Day 14 after colonoscopy]
- Change in flatulence intensity score [Time frame: 48 hours, Day 7, and Day 14 after colonoscopy]
- Change in stool consistency assessed by Bristol Stool Form Scale [Time frame: 48 hours, Day 7, and Day 14 after colonoscopy]
- Change in frequency of bowel movements [Time frame: 48 hours, Day 7, and Day 14 after colonoscopy]
- Global Assessment of Change of Gastrointestinal Symptoms (PGIC) score at Day 7 [Time frame: 48 hours, Day 7, and Day 14 after colonoscopy]
- Proportion of participants with clinically relevant improvement in gastrointestinal symptoms [Time frame: 48 hours, Day 7, and Day 14 after colonoscopy]
- Use of rescue medication for gastrointestinal symptoms [Time frame: Within 14 days after colonoscopy]
- Frequency of adverse events [Time frame: Within 14 days after colonoscopy]
- Treatment tolerability score [Time frame: Day 14 after colonoscopy]
- Adherence to treatment [Time frame: Within 14 days after colonoscopy]
Eligibility criteria
Inclusion criteria
- Age between 18 and 80 years
- Complete diagnostic colonoscopy with achievement of the cecal fundus
- Accepted written informed consent for study participation obtained prior to the start of the study
Exclusion criteria
- Chronic inflammatory bowel disease
- Complicated Diverticular Disease (DICA >3)
- Suspected or known colorectal malignancy on index colonoscopy
- Diagnosed microscopic colitis
- Operative colonoscopy
- Severe chronic gastrointestinal symptoms judged by the investigator to interfere with the evaluation of study endpoints
- Subjects who are immunosuppressed or on systemic immunosuppressive treatment, including patients with primary or acquired immunodeficiency, oncological disease on active treatment with chemotherapy/immunotherapy, or autoimmune diseases on immunosuppressive treatment
- Taking probiotics, prebiotics, or synbiotics within 2-4 weeks prior to enrollment
- Antibiotic therapy within 4 weeks prior to enrollment
- Lack of acceptance of written informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Italy · 1 center
- University of Urbino Carlo Bo, Urbino, Italy — Urbino
Identifiers
NCT: NCT07519616 · 139_16luglio2025_COLIPRAL